109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
Compositions and methods
#2402Compositions and methods for modulating HBV expression
#2403siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
#2404Compositions and methods for modulation nucleic acids through nonsense mediated decay
#2405Modulation of androgen receptor expression
#2406Modulation of dystrophia myotonica-protein kinase (DMPK) expression
#2407miR-29 mimics and uses thereof
#2408RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
#2409Synthetic mimics of miR-124
#2410MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#2411SYNTHETIC MIMICS OF MIR-34
#2412Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
#2413Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
#2414Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
#2415COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#2416Treatment of genetic disorders associated with DNA repeat instability
#2417Modulation of hepatitis B virus (HBV) expression
#2418Aptamer to IL-17 and use thereof
#2419Targeting microRNAs for the treatment of liver cancer
#2420Methods for enhancing utrophin production via inhibition of microRNA
#2421Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#2422Oligonucleotides for modulating gene expression and uses thereof
#2423Modulation of RNA activity and vascular permeability
#2424Non-liposomal systems for nucleic acid delivery
#2425RNA sequence-specific mediators of RNA interference
#2426Inhibitors of MYH7B and uses thereof
#2427Compositions and methods for modulating Tau expression
#2428ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
#2429Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT
#2430Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
#2431Oligomers
#2432Compositions and methods for inhibition of expression of protein C (PROC) genes
#2433Methods for monitoring C9ORF72 expression
#2434Compositions and Methods for Inhibiting Expression of Eg5 Gene
#2435COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENE
#2436PCSK9 iRNA compositions and methods of use thereof
#2437Serpinc1 iRNA compositions and methods of use thereof
#2438Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2439DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#2440Reducing intron retention
#2441Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
#2442Locked nucleic acid inhibitor of miR-145 and uses thereof
#2443Organic compositions to treat EPAS1-related diseases
#2444Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#2445Multiple exon skipping compositions for DMD
#2446Multiple exon skipping compositions for DMD
#2447Multiple exon skipping compositions for DMD
#2448Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2449Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2450METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS
#2451Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#2452Multiple exon skipping compositions for DMD
#2453Multiple exon skipping compositions for DMD
#2454Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2455Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2456CCCTC-Binding Factor (CTCF) RNA Interactome
#2457Lipid formulations for delivery of therapeutic agents to solid tumors
#2458USE OF VEGFR1 AS A BIOMARKER
#2459OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
#2460EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2461Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
#2462Lipids, lipid complexes and use thereof
#2463Aptamer against midkine and applications thereof
#2464Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2465Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
#2466Methods and compositions involving miRNA and miRNA inhibitor molecules
#2467Compounds and methods for modulating gene expression
#2468dsRNA For Treating Viral Infection
#2469Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2470Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2471Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2472Methods and compositions for modulating apolipoprotein (a) expression
#2473Methods of treating ischemia-reperfusion injury with siRNAs
#2474SELECTIVE REDUCTION OF ALLELIC VARIANTS
#2475Oligomeric compounds and compositions for the use in modulation of micrornas
#2476Post-synthetic orthogonal amidation plus metal catalyzed azide-alkyne cycloaddition click chemistry on siRNA
#2477Methods and compositions of improved modified siRNA
#2478SNPs OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION
#2479COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#2480Antisense modulation of PTP1B expression
#2481Compositions and methods for modulating angiopoietin-like 3 expression
#2482Compositions and methods for silencing apolipoprotein C-III expression
#2483Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
#2484Deep intronic target for splicing correction on spinal muscular atrophy gene
#2485COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS
#2486DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#2487Compositions and methods for selective delivery of oligonucleotide molecules to cell types
#2488Composition and method for treating a hematological malignancy
#2489Compositions and their uses directed to huntingtin
#2490Composition for treating cancer associated with HPV infection
#2491Methods for treatment of alport syndrome
#2492Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#2493SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
#2494MODULATION OF CD40 EXPRESSION
#2495Organic compositions to treat beta-catenin-related diseases
#2496RNAi inhibition of alpha-ENaC expression
#2497Methods of treating kennedy's disease
#2498Organic compositions to treat HSF1-related diseases
#2499Oligonucleotide complex compositions and methods of use as gene alteration tools
#2500Organic compositions to treat beta-ENaC-related diseases
#2501RIG-I ligands and methods for producing them
#2502Methods and compositions for inhibition of immune responses and autoimmunity
#2503METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
#2504Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
#2505RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2506Oligomeric compounds comprising bicyclic nucleosides and uses thereof
#2507Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof
#2508Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#2509Short interfering ribonucleic acid (siRNA) for oral administration
#2510Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2511Modulation of transthyretin expression
#2512Complement component C5 iRNA compositions and methods of use thereof
#2513ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY
#2514Methods and compositions for the specific inhibition of MYC by double-stranded RNA
#2515Euchromatic region targeting methods for modulating gene expression
#2516UNA oligomers targeting micro-RNA for therapeutics
#2517Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
#2518UNA duplex oligomers for therapeutics
#2519TARGETING OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING FXN RNA
#25205' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#2521METHODS FOR MODULATING RNA USING 5' TARGETING OLIGONUCLEOTIDES
#2522Methods for use in modulating miR-122A
#2523Methods and compositions for treating neurological disease
#2524COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#2525Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#2526Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#2527METHODS FOR SELECTIVE TARGETING OF HETEROCHROMATIN FORMING NON-CODING RNA
#2528Selective reactivation of genes on the inactive X chromosome
#25293' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#2530SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
#2531Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2532Restoration of the CFTR function by splicing modulation
#2533Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry
#2534Methods of treatment using TLR7 and/or TLR9 inhibitors
#2535Oligonucleotide comprising an inosine for treating DMD
#2536Double-stranded oligonucleotide molecules to P53 and methods of use thereof
#2537Method for Generating Aptamers with Improved Off-Rates
#2538Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#2539Modified RNAi agents
#2540Methods and compositions for treating prostate cancer
#2541Modulation of UBE3A-ATS expression
#2542COMPOSITIONS AND METHODS FOR MODULATING APOA1 AND ABCA1 EXPRESSION
#2543ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION
#2544MODULATION OF TRANSTHYRETIN EXPRESSION
#2545MODULATION OF APOLIPOPROTEIN (a) EXPRESSION
#2546Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#2547Compositions and methods for modulating HBV expression
#2548Antisense modulation of superoxide dismutase 1, soluble expression
#2549Oligomeric compounds and methods
#2550Methods for treating hypercholesterolemia
#2551Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene
#2552Antisense nucleic acids
#2553Compositions and methods for inhibition of nucleic acids function
#2554Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues
#2555Lipid formulations
#2556COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
#2557Compositions and methods for modulating ATP2A2 expression
#2558Aptamer therapeutics useful in the treatment of complement-related disorders
#2559Modulation of huntingtin expression
#2560Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#2561Compounds and methods for altering RSV replication rate
#2562Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#2563Chemical modification of short small hairpin RNAs for inhibition of gene expression
#2564siRNA compounds comprising terminal substitutions
#2565METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#2566RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2567RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#2568Antisense modulation of GCCR expression
#2569RNA interference mediating small RNA molecules
#2570COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#2571Therapeutic micro RNA targets in chronic pulmonary diseases
#2572COMPOSITIONS AND METHODS FOR MODULATING BDNF EXPRESSION
#2573Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#2574Compositions and methods for modulating apolipoprotein (a) expression
#2575Compositions and methods for modulating apolipoprotein C-III expression
#2576Conjugated antisense compounds and their use
#2577Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#2578Micro-RNA inhibitors and their uses in disease
#2579Transferrin receptor aptamers and aptamer-targeted delivery
#2580Compositions and Methods for Inhibiting Expression of RRM2 Genes
#2581Compositions and methods for silencing ebola virus gene expression
#2582Compositions and methods for inhibiting expression of the ALAS1 gene
#2583Interfering RNA molecules
#2584Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
#2585MicroRNA compounds and methods for modulating miR-122
#2586Antisense modulation of GCGR expression
#2587Compositions and methods for modulating UTRN expression
#2588Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#2589Methods and compositions for modulating alpha-1-antitrypsin expression
#2590Peptide-conjugated oligonucleotide therapeutic and method of making and using same
#2591Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
#2592Targeting micrornas for the treatment of fibrosis
#2593Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
#2594Glycoconjugates of RNA interference agents
#2595Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA
#2596Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
#2597Double-stranded oligonucleotides
#2598COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB
#2599INHIBITORS OF NOX4 EXPRESSION AND /OR NOX4 FUNCTION AND THEIR USE IN THE PREVENTION AND TREATMENT OF NERVE INJURY AND/OR NEUROPATHIC PAIN
#2600Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#2601Targeting MicroRNAs for metabolic disorders
#2602Compositions and methods for treatment of ovarian cancer
#2603TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF
#2604METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION
#2605Methods and compositions for neuroprotection
#2606COMPOSITIONS AND METHODS FOR MODULATION OF IKBKAP SPLICING
#2607Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
#2608Methods for Treating or Preventing Ophthalmological Conditions
#2609Methods and compositions for reducing viral genome amounts in a target cell
#2610Methods and compositions involving miRNA and miRNA inhibitor molecules
#2611Modulation of T cell signaling threshold and T cell sensitivity to antigens
#2612MODULATION OF RNA BY REPEAT TARGETING
#2613Double-stranded RNA compounds to CASP2 and uses thereof
#2614Reduced size self-delivering RNAi compounds
#2615CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY
#2616Modulation of hepatitis B virus (HBV) expression
#2617MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#2618COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
#2619MicroRNA compounds and methods for modulating miR-122
#2620Methods and compositions involving miRNA and miRNA inhibitor molecules
#2621Compositions and methods for inhibiting expression of the PCSK9 gene
#2622Extended dicer substrate agents and methods for the specific inhibition of gene expression
#2623Antisense nucleic acids
#2624Conjugated antisense compounds and their use
#2625Compositions and methods for inhibiting expression of factor VII gene
#2626Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2627Compositions and methods for prognosis and treatment of prostate cancer
#2628Antisense oligonucleotides for the treatment of Leber congenital amaurosis
#2629Anti-microRNA oligonucleotide molecules
#2630Lipids, lipid complexes and use thereof
#2631Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
#2632Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#2633Oligonucleotide modulators of the toll-like receptor pathway
#2634Means for inhibiting the expression of ANG2
#2635Selective antisense compounds and uses thereof
#2636Methods and compounds useful in conditions related to repeat expansion
#2637RNA interference in skin indications
#2638Methods and compositions involving miRNA and miRNA inhibitor molecules
#2639Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
#2640Antisense antiviral compound and method for treating influenza viral infection
#2641Compositions and methods for inhibiting expression of the HAMP gene
#2642Methods and compositions for the specific inhibition of beta-catenin by double stranded RNA
#2643Modified RNAi agents
#2644Exon skipping therapy for dystrophic epidermolysis bullosa
#2645Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#2646Modulation of transthyretin expression
#2647Compositions and methods for silencing aldehyde dehydrogenase
#2648Compositions and methods for inhibiting expression of a gene from the Ebola virus
#2649Clusterin antisense therapy for treatment of cancer
#2650Modulation of HSP47 expression
#2651Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#2652Targeting microRNAs for the treatment of liver cancer
#2653Compositions and methods for inhibiting expression of transthyretin
#2654Sequence-specific inhibition of small RNA function
#2655Modulation of angiopoietin-like 3 expression
#2656Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
#2657Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
#2658Use of VEGFR1 as a biomarker
#2659Spinal muscular atrophy treatment via targeting SMN2 catalytic core
#2660Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#2661Compositions and methods for inhibition of expression of protein C (PROC) genes
#2662Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
#2663Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2664Microrna (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2665Antisense compounds targeting genes associated with usher syndrome
#2666Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
#2667Method of treating cancer by inhibition of DNA repair proteins
#2668Modulation of hepatitis B virus (HBV) expression
#2669Synthetic mimics of miR-34
#2670Modulation of androgen receptor expression
#2671Organic compositions to treat Beta-ENaC-related diseases
#2672Methods and compositions for the specific inhibition of MYC by double-stranded RNA
#2673Methods for treatment of alport syndrome
#2674TRPM-2 antisense therapy
#2675SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#2676Antisense modulation of fibroblast growth factor receptor 4 expression
#2677dsRNA for treating viral infection
#2678Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#2679RNAi modulation of ApoB and uses thereof
#2680Organic compositions to treat HSF1-related diseases
#2681Lipid nano particles comprising cationic lipid for drug delivery system
#2682Oligonucleotides for modulation of target RNA activity
#2683Compositions and methods for modulating angiogenesis
#2684Chimeric oligomeric compounds for modulation of splicing
#2685Compositions and methods for treating lung disease and injury
#26865′-end derivatives
#2687Modulation of apolipoprotein C-III expression
#2688Serpinc1 iRNA compositions and methods of use thereof
#2689Therapeutic uses of inhibitors of RTP801L
#2690Base modified oligonucleotides
#2691Compounds and methods for modulating interaction between proteins and target nucleic acids
#2692Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
#2693Compositions and their uses directed to huntingtin
#2694Compositions and methods for inhibiting expression of the ALAS1 gene
#2695Compositions and methods for inhibiting expression of Eg5 gene
#2696RNAi modulation of SCAP and therapeutic uses thereof
#2697Gene silencing by single-stranded polynucleotides
#2698Micro-RNA family that modulates fibrosis and uses thereof
#2699Micro-RNA family that modulates fibrosis and uses thereof
#2700RNAi sequence-independent modification formats, and stabilized forms thereof